{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:59:25Z","timestamp":1788609565772,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/ico.0b013e31826af7b8","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T05:17:45Z","timestamp":1352179065000},"page":"810-815","source":"Crossref","is-referenced-by-count":31,"title":["Treatment of Mucous Membrane Pemphigoid With Mycophenolate Mofetil"],"prefix":"10.1097","volume":"32","author":[{"given":"Jennifer M.","family":"Nottage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Hammersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann P.","family":"Murchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Felipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Penne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Raber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-17-20210204","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/bjo.2006.092528","article-title":". Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa.","volume":"90","author":"Higgins","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R3-17-20210204","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.76.6.332","article-title":". Dapsone therapy for the acute inflammatory phase of ocular pemphigoid.","volume":"76","author":"Fern","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"R4-17-20210204","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0161-6420(01)00657-1","article-title":". Treatment of ocular cicatricial pemphigoid with sulfasalazine.","volume":"108","author":"Doan","year":"2001","journal-title":"Ophthalmology"},{"key":"R5-17-20210204","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":". Methotrexate for ocular inflammatory disease. SITE Cohort Study.","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"R6-17-20210204","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":". Azathioprine for ocular inflammatory diseases.","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R7-17-20210204","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":". Cyclophosphamide for ocular inflammatory disease.","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-17-20210204","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2008.08.002","article-title":". Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.","volume":"115","author":"Thorne","year":"2008","journal-title":"Ophthalmology"},{"key":"R9-17-20210204","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","article-title":". Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.","volume":"111","author":"Sami","year":"2004","journal-title":"Ophthalmology"},{"key":"R10-17-20210204","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.eye.6702948","article-title":"Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-.","volume":"21","author":"John","year":"2004","journal-title":"Eye (Lond)"},{"key":"R11-17-20210204","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archderm.142.10.1268","article-title":"Successful treatment of mucous membrane pemphigoid with infliximab.","volume":"142","author":"Heffernan","year":"2006","journal-title":"Arch Dermatol"},{"key":"R12-17-20210204","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"R13-17-20210204","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ophtha.2005.02.020","article-title":". Mycophenolate mofetil therapy for inflammatory eye disease.","volume":"112","author":"Thorne","year":"2005","journal-title":"Ophthalmology"},{"key":"R14-17-20210204","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":". Mycophenolate mofetil for ocular inflammation.","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R15-17-20210204","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0161-6420(03)00092-7","article-title":". Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders.","volume":"110","author":"Baltatzis","year":"2003","journal-title":"Ophthalmology"},{"key":"R16-17-20210204","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":". Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"key":"R17-17-20210204","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":". Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"key":"R18-17-20210204","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-2008-1027134","article-title":". Mycophenol acid in ocular autoimmune disorderscan we optimize this therapy in German.","volume":"225","author":"Pleyer","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"key":"R19-17-20210204","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-2001-14917","article-title":". Early clinical experiences with mycophenolate mofetil for immunosuppressive therapy of ocular cicatricial pemphigoid in German.","volume":"218","author":"Zurdel","year":"2001","journal-title":"Klin Monbl Augenheilkd"},{"key":"R20-17-20210204","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(99)90078-7","article-title":"Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease.","volume":"106","author":"Larkin","year":"1999","journal-title":"Ophthalmology"},{"key":"R21-17-20210204","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"R22-17-20210204","first-page":"782","article-title":"Moser G, et al..","volume":"96","author":"Miehsler","year":"2001","journal-title":"Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohns disease Am J Gastroenterol"},{"key":"R23-17-20210204","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1191\/096120301673517315","article-title":"Treatment of systemic lupus erythematosus with mycophenolate mofetil.","volume":"10","author":"Adu","year":"2001","journal-title":"Lupus"},{"key":"R24-17-20210204","first-page":"527","article-title":"Cicatricial pemphigoid.","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R25-17-20210204","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0151-9638(05)79188-2","article-title":". Cicatricial pemphigoid: treatment with mycophenolate mofetil in French.","volume":"132","author":"Ingen-Housz-Oro","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"R26-17-20210204","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1067\/mjd.2001.114746","article-title":"Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent.","volume":"45","author":"Megahed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R27-17-20210204","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/TP.0b013e3182003d76","article-title":". Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.","volume":"91","author":"Ciancio","year":"2011","journal-title":"Transplantation"},{"key":"R28-17-20210204","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/TP.0b013e3181ca860d","article-title":". Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.","volume":"89","author":"Sollinger","year":"2010","journal-title":"Transplantation"},{"key":"R29-17-20210204","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":". Cyclosporine for ocular inflammatory diseases.","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology"},{"key":"R30-17-20210204","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ophtha.2003.03.001","article-title":"Mucous membrane pemphigoid and pseudopemphigoid.","volume":"111","author":"Thorne","year":"2004","journal-title":"Ophthalmology"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e31826af7b8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T15:34:27Z","timestamp":1621870467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201306000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31826af7b8","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}